NCT00005872 2013-12-04
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
11 trialsNCT00005873 2013-12-04
Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005875 2013-12-04
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005876 2013-12-04
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005877 2013-12-04
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00006267 2013-07-09
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Withdrawn
NCT00005826 2012-09-24
Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00006026 2012-09-24
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00006082 2012-09-24
Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00006230 2012-09-24
Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00249990 2010-01-07
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
University of New Mexico
Phase 2 Completed